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1 Introduction
Early treatment of hypothyroid neonates is
essential to prevent mental retardation. This
goal can be achieved by neonatal hy-
pothyroidism screening which has proved to be
a rapid and effective method to detect
hypothyroid newborns [3]. In pregnancies at
risk for the presence of fetal hypothyroidism,
such as hyperthyroid mothers accidentally
treated with 131I after 10 weeks of pregnancy
or treated with antithyroid drugs, it seems
reasonable to make an in utero diagnosis of
fetal hypothyroidism. Medical treatment of the
hypothyroid fetus by the administration of
thyroxine (T4) into the amniotic cavity or in-
tramuscularly may be effective [17, 28] although
cord blood (CB) TV and Ts concentrations were
undetectable and TSH concentration was el-
evated in the fetus treated intramuscularly [17].
The diagnosis of intrauterine hypothyroidism
has been attempted by measurement of T4 or
FBI in amniotic fluid (AF) resulting in values
apparently reflecting thyroid function in the
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neonate [10]. However, the concentrations of
T4 and triiodothyronine (Ts) in unconcentrated
AF are low or undetectable and, therefore,
these tests may not be clinically useful in detect-
ing fetal hypothyroidism [4, 26]. Measurement
of AF reverse Ts (rTs) has been proposed as a
useful method to detect fetal hypothyroidism
[4]. However, low AF rTs was not useful in
detecting a few patients with proven fetal hy-
pothyroidism [16].
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More recently it has been suggested that meas- times of TRH injection, CB and AF sampling
urement of AF thyrotropin (TSH) could be a were recorded. AF specimens contaminated
reliable test to diagnose primary fetal hy- with blood or meconium were not included,
pothyroidism [27], although this is somewhat Only AF which was clear by visual inspection
controversial [21]. In support of this possibility, was evaluated. Portions of all the AF specimens
KOURIDES et al. have reported that TSH can be were concentrated 4 fold by lyophilization and
detected in 3 to 8 fold concentrates of AF and then reconstituted in 0.01 M Na P 4, pH 7.4,
have suggested that an elevation of AF TSH 0.25% bovine serum albumin buffer. Serum
may be useful in the diagnosis of primary fetal and AF specimens were kept frozen at —20 °C
hypothyroidism [13]. The present study was until analysis. Except for a few specimens, TSH,
undertaken to determine whether fetal T4, Ta and rH were measured in all CB and
hyperthyrotropinemia, induced by the ad- unconcentrated AF samples. TSH was also
ministration of thyrotropin releasing hormone measured in the concentrated AF samples.
(TRH) to the mothers during labor [23], would
 Hormone anaiyses: TSH was measured by RIA
result in an increase in AF TSH concentrations
 mi materials obtained from the National
obtained during labor and delivery. Pituitary Agency, NIAMDD (Bethesda, MD);
300 μΐ of serum or AF or buffer were employed
in the TSH assay. The protein content in clear,
2 Material and methods concentrated AF was approximately 250 mg/
dl, 92 percent of which is albumin. The diluent
After informed consent was obtained by the for the standard curve used in the measurement
obstetrician prior to labor, 65 women with
 of AF TSH consisted of phosphate buffer,
uncomplicated pregnancies were studied at
 0 01 M> pH 7 4? enriched with human serum
term. Sixteen received an iv injection of 2 ml of
 albumin (HSA) to approximate the con-
saline and the others, selected at random, were centration of protein in AF. This concentration
treated with 400 μ§ synthetic TRH iv (Biodata, of HSA did not affect the standard curve. The
Milan, Italy). After the umbilical cord was cut,
 recovery of human TSH added to AF is 100
CB was obtained from the placental side of
 percent. The lowest detectable TSH con-
the cord which represents fetal blood and is a
 centration was 0.2 μυ/tube corresponding to
mixture of arterial and venous blood. Samples
 0 6 μυ/ηι1 Τ4 was measured in serum and AF
of amniotic fluid were obtained in one of 2
 by RIA using materiai supplied by Biodata.
ways. In the 31 women who were delivered by
 Semm and AF Ta and rTs were measured by
Caesarian section, amniocentesis was per- methods previously described [1,19]. Sensitivity
formed through the fetal membranes after
 of the assays for the thyroid hormones are: T4,
uterine incision. Ammorexis is a common
 0 6 μβ/α1; y3 62 /dl; τΎ^ 25 /dl
practice during labor in these obstetrical units.
Therefore, in the 34 women who were delivered M samples were assayed for each hormone in
vaginally, amniocentesis was carried out under duplicate, in the same assay and in random
direct visualization through the fetal sac after OI>der.
it protruded through the dilated cervical os. In Data analysis: Hormone values in CB and AF
some women, vaginal amniocentesis was samples from mothers treated with saline were
carried out on 2 occasions. In both groups of assigned to one group (group 0). Hormone con-
women, AF was obtained only if a sufficient centrations in CB and AF specimens from
volume of AF was interposed between the fetus women treated with TRH were assigned to dif-
and fetal membranes. All amniocenteses were ferent groups (1 to 5) depending upon the dura-
carried through a 140 mm, 0.7 mm gauge tion of time between TRH administration and
needle. No adverse effects were observed during CB and AF samples. There was no significant
labor and delivery or during the neonatal difference in gestational age or birth weight
period following TRH administration. The among the various groups.
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Statistical analysis was carried out by one way
analysis of variance (ANOVA, F test) and
Duncan's multiple range test corrected for an
unequal number of determinations [14] to com-
pare the value of group 0 (saline treated) and
groups 1 to 5 (TRH treated). All results are
reported as the mean + SE.
3 Results
TSH concentrations in CB and in un-
concentrated AF are shown in Fig. 1. In group
0, CB TSH was 5.0 ± 0.3 μΠ/ml. A significant
variation in CB TSH concentration was
observed in groups whose mothers received
TRH (p < 0.01, F test). A peak value of
38.0 + 4.2 μυ/ml was observed in group 2,
sampled from 61 to 120 min after TRH. This
value was highly significant vs values obtained
in group 0 (p < 0.01, Duncan's test). A sig-
nificant increase in TSH, as compared to group
0, was observed in groups 1 and 3 (p < 0.01,
Duncan's test) and also in group 4 sampled
from 181 to 240 min after TRH (p < 0.05,
Duncan's test).
TSH was below the limit of detectability in
unconcentrated AF samples obtained from all
groups. TSH was also undetectable in AF
samples concentrated 4 fold except for two
specimens sampled at 75 and 140 min after
TRH administration (1.3 and 1.0 μυ/ml, re-
spectively) and in three samples in group 0 with
values of 1.0 μυ/ml. In AF specimens con-
taminated with blood, not included in these
groups, TSH concentrations as high as 2.3 μΐΐ/
ml were observed.
The concentrations of T4, TB and rTs in cord
blood confirmed our earlier findings (23) (Tab.
I). In group 0, the mean T4 concentration was
10.9 ± 0.5 μg/dl. In groups 1 to 5, a significant
increase was observed p < 0.01 (F test) with a
peak value of 14.7 ± 0.9 μg/dl in group 4
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Fig. 1. TSH concentration in CB (—) and in non concentrated AF samples (*) of group 0 (control) and groups 1
to 5 (TRH treated) sampled at different time intervals after maternal TRH administration. The values are reported
as the mean ± SE. The number of observations for each group is noted in the parentheses. The dotted line
represents the limit of detectability of the TSH assay (0.6 μυ/ml).
J. Perinat. Med. 13 (1985)
222 Robuschi et al., Amniotic fluid TSH
_ - -· ·· - — — —
sampled 181 to 240 min after TRH ad- dl in group 3, sampled 121 to 180min after
ministration. Ts concentration was 43.4 ± TRH administration. CB rTa concentration was
3.7 ng/dl in group 0 and a significant increase similar in control and TRH treated mothers,
was observed in groups 1 to 5, p < 0.01 (F The concentrations of iodothyronines in
test), reaching a peak value of 107.3 ± 5.6 ng/ unconcentrated AF are reported in Tab. II. T4
Tab. I. T4, T3 and rT3 concentrations in cord blood (CB) from control (group 0) and TRH treated women (groups
1 to 5).
Groups
T4
fog/dl)
T3(ng/dl)
rT3(ng/dl)
0
10.9C
0.5d
16e
43.4
3.7
16
242.5
13.9
16
1 2 3 4
15-60a 61-120 121-180 181-240
38.3 + 2.8b 86.9 + 8.5 156.8 ± 4.3 220.9 ± 7
12.0
0.7
8
67.6
9.6
9
256.9
11.9
9
12.3
0.7
9
94.2
4.5
14
257.9
17.4
12
13.5
0.6
10
107.3
5.6
12
248.4
14.6
12
14.7
0.9
6
73.9
8.2
6
282.1
20.5
6
5
241-2970
.8 1026.5 ± 313.5
12.5
0.7
7
49.1
7.2
8
251.9
11.4
8
F testf p < 0.01
F test p < 0.01
F test NS
a
 The range of time (minutes) between maternal TRH administration and CB samples
b
 The mean ± SE of time (minutes) between maternal TRH administration and CB samples
c
 The mean of values for each hormone
d
 ± SE
e
 Number of observations
f
 ANOVA test including all groups
Tab..II. T4, Ts and rTs concentrations in unconcentrated amniotic fluid (AF) samples of control (0 group) and
TRH treated women (groups 1 to 5).
Groups
T4
^g/dl)
T3
(ng/dl)
rT3
(ng/dl)
0
1.3C
O.ld
16e
<6.25
0
16
55.6
9.5
15
1
0-60a
39 + 3.3b
1.3
0.4
20
<6.25
0
21
46.4
5.9
21
2
61-120
90.9 ± 4.5
1.2
0.1
19
<6.25
0
19
51.5
6.6
20
3
121-180
160.7 + 3.7
1.1
0.1
16
<6.25
0
15
54.4
5.4
16
4
181-240
207 ± 9.8
1.0
0.2
5
<6.25
0
5
55.2
9.6
5
5
241-2970
813.6 ± 86.7
0.8
0.1
13 .
<6.25
0
15
52.6
9.2
15
F testf NS
F test NS
F test NS
a
 The range of time (minutes) between maternal TRH administration and AF samples
b
 The mean ± SE of time (minutes) between maternal TRH administration and CB samples
c
 The mean of values for each hormone
d
 ± SE
e
 Number of observations
f
 ANOVA test including all groups
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concentration in AF in all groups was barely
detectable and no variation was observed. Ts
was not detectable in any of the samples. rTs
concentrations in group 0 and in groups 1 to 5
ranged between 46.4 and 55.6 ng/dl and did not
differ between groups.
4 Discussion
Neonatal thyroid screening has provided a use-
ful tool for the detection of hypothyroid
newborns resulting in early treatment of these
infants, thus avoiding permanent mental re-
tardation due to thyroid hormone deficiency
during the neonatal period. However, possible
approaches to the intrauterine diagnosis of fetal
hypothyroidism have been suggested [27].
Measurement of rTs in AF was proposed as
a possible approach to evaluate fetal thyroid
function [9]. However, later studies have in-
dicated that this test was not useful in di-
agnosing fetal hypothyroidism [16]. In the rat,
it has been demonstrated that AF rTs is more
dependent upon maternal thyroid function than
fetal thyroid status [6] and it has been post-
ulated that fetal rTs arises, at least in part, from
the inner ring deiodination of T4 by placenta
and fetal membranes [22, 24, 25].
Recently, KOURIDES et al. [13] have detected
TSH in 3 to 8 fold concentrates of AF sug-
gesting the possibility of diagnosing primary
fetal hypothyroidism. In a previous study we
were able to detect TSH in only a few specimens
of AF [20]. In the present report, TSH was not
detectable in the unconcentrated AF samples.
After a 4 fold concentration, TSH was still
undetectable in almost all AF samples obtained
in saline and TRH treated women at term.
These conflicting results are probably due to
the different sensitivities of the two TSH assays,
0.15μυ/πι1 [10] vs 0.6 μυ/ml (present study).
The aim of the present study, however, was to
evaluate whether a marked increase in fetal
serum TSH would result in a corresponding
elevation in AF TSH. After the administration
of TRH to the term pregnant woman, CB TSH
concentrations were markedly increased, reach-
ing values as high as 63.3 μυ/ml. This increase
in CB TSH did not result in a detectable in-
crease in AF TSH even when the AF was con-
centrated 4 fold. In the adult, TSH has a bio-
logical half life of 50 — 60 minutes and is mainly
metabolized by the kidney. Moreover, im-
munoreactive TSH is not found in the urine [5].
In the newborn, the half life of endogenous
TSH is 77 minutes [8]. It is not known how
fetal TSH reaches the amniotic fluid. Possible
sources of AF TSH include fetal urinary ex-
cretion, if the fetal kidney excretes intact TSH,
which seems unlikely in view of the data noted
above in the adult and newborn, or passage
through the pars placentaris of the amnion
from the chorion plate and placenta. It is pos-
sible, however, that the fetal kidney in mid
gestation might not degrade the elevated serum
TSH present in hypothyroidism which could
result in urinary excretion of and a subsequent
elevation in amniotic fluid TSH. Degradation
of fetal TSH by AF does not seem likely. Pre-
vious studies have demonstrated that a small
peptide like TRH is not degraded by AF in
vitro [18] and other protein hormones, such
as prolactin and growth hormone, are readily
detectable in AF [2].
In a previous study, AF TSH measured before
T4 injection into the amniotic cavity was
undetectable in suspected fetal hypothyroidism
due to maternal treatment with 131I at 10 — 11
weeks of pregnancy [17]. In other cases of pro-
ven fetal hypothyroidism, AF TSH un-
fortunately was not measured [16, 7].
HOLLINGSWORTH et al. have reported high con-
centrations of AF TSH in the sheep following
fetal hypothyroidism induced by intrauterine
thyroidectomy [11]. The presence of high con-
centrations of TSH in AF may be due to the
different placental structure in the sheep com-
pared to man. The ovine placenta consists of
separate cotyledons whereas the human
placenta is a single mass. Furthermore,
although unlikely, serum TSH could have
reached the AF through the surgical thy-
roidectomy scar. In the present study, AF TSH
was elevated in saline and TRH treated women
when the AF samples were contaminated with
blood.
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Although elevations of fetal serum TSH con-
centrations for as long as 4 hours did not result
in elevated AF TSH concentrations in the pre-
sent study, it should be emphasized that fetal
hypothyroidism is most often due to thyroid
agenesis or dysgenesis [15] which would result
in a more prolonged and greater elevation of
fetal serum TSH. Whether the longer duration
of an even higher elevation of fetal serum TSH
concentrations would result in an increase in
AF TSH remains conjectural. It should also be
emphasized that the present study was carried
out in the term fetus and it is possible that
elevations in serum TSH in mid gestation might
result in an increase in TSH content in the
amniotic fluid at that time. However, since this
study was completed, HOLLINGSWORTH and
ALEXANDER reported that measurements of AF
concentrations of thyroid hormones and TSH
do not reliably predict fetal or neonatal thyroid
status [12].
Summary
Cord blood and amniotic fluid thyrotropin (TSH), T4,
Ta, and rTs concentrations were measured in 49 women
who received 400 § thyrotropin releasing hormone
(TRH) iv during labor and in 16 control women who
received saline. Cord blood serum TSH concentrations
were elevated for as long as 4 hours after TRH ad-
ministration and peak values (38.0 ± 4.2 /ml) were
observed from 61 — 120 minutes after TSH as compared
to control values of 5.0 ± 0.3 /ml. The elevations in
fetal TSH concentration stimulated the fetal thyroid,
resulting in a progressive increase in cord blood T4 and
Ts but not rTs concentrations. These TRH induced
elevations in fetal cord blood TSH concentrations were
not accompanied by increases in unconcentrated and 4
fold concentrated amniotic fluid TSH concentrations
which were almost always below 0.6 /ml, the limit
of assay sensitivity. Unconcentrated amniotic fluid T4
concentrations were barely detectable and no variation
was observed between the TRH treated and saline treat-
ed mothers; amniotic fluid Ta was not detectable in any
of the groups; and amniotic fluid rTs concentrations
ranged between 46.4 and 55.6 ng/dl and did not differ
between groups.
These findings suggest that term amniotic fluid TSH
values do not reflect transient but marked elevations in
fetal serum TSH concentrations and that amniotic fluid
TSH determination is probably not useful in the detection
of primary fetal hypothyroidism. It is possible, but un-
likely, that long-term and even greater elevations in fetal
serum TSH concentrations would result in increased
amniotic fluid TSH concentrations. Thus, there appears
to be little use in measuring amniotic fluid TSH con-
centrations for diagnosing fetal hypothyroidism.
Keywords: Amniotic fluid, thyrotropin, thyrotropin releasing hormone.
Zusammenfassung
TSH im Fruchtwasser nach Gabe von TRH an die Mutter
In 49 Fällen, in denen die Mutter unter der Geburt
400 g TRH erhalten hatte, wurden im Nabelblut und
im Fruchtwasser die Konzentrationen von TSH, T4, Ta
und rT3 bestimmt. Die Kontrollgruppe mit 16 Frauen
erhielt NaCl. Die TSH-Konzentration im Nabelblut war
bis zu 4 h nach der TRH-Gabe erhöht. Peaks (38.0 ±
4.2 /ml) zeigten sich zwischen 61 —120min nach
TRH-Gabe; in der Kontrollgruppe lagen die Peaks bei
5.0 ± 0.3 /ml. Die erhöhte fetale TSH-Konzentration
führte über die Stimulation der Schilddrüse zu einem
steilen Anstieg von Ts und T4, nicht aber rTs im Nabel-
blut. Dagegen waren die TSH-Werte sowohl in nichtkon-
zentriertem wie auch in vierfach konzentriertem Frucht-
wasser nicht erhöht; sie lagen immer unter der Nachweis-
grenze von 0.6 /ml. T4 war im Fruchtwasser kaum
nachweisbar; es zeigte sich kein Unterschied zwischen
Schlüsselwörter: Fruchtwasser, TSH, TRH.
der behandelten Gruppe und der Kontrollgruppe. Ta
war im Fruchtwasser überhaupt nicht nachweisbar. Die
rTa-Konzentration variierte sowohl in der unbehandel-
ten wie auch in der behandelten Gruppe zwischen 46.4
und 55.6 ng/dl.
Unsere Ergebnisse zeigen, daß die TSH-Werte im
Fruchtwasser am Termin deutliche, wenn auch vorüber-
gehende Anstiege der fetalen TSH-Werte im Serum nicht
widerspiegeln. Die TSR-Bestimmung im Fruchtwasser
scheint damit für die Aufdeckung einer primären fetalen
Hypothyreose ungeeignet. Möglicherweise könnten län-
ger anhaltende und auch stärkere Anstiege der TSH-
Konzentration im fetalen Serum erhöhte TSH-Werte im
Fruchtwasser bewirken. Uns erscheint jedoch die Mes-
sung von TSH im Fruchtwasser für die Diagnose einer
fetalen Hypothyreose wenig brauchbar.
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Resume
Thyreotropine (T. S. H.) dans le liquide amniotique apres
administration maternelle de thyreotropine releasing hor-
mone
On a mesuro chez 49 femmes ayant re?u 400 microgram-
mes de thyreotropine releasing hormone en I. V. au cours
du travail, ainsi que chez 16 femmes contrölees ayant
re?u un serum sale, les concentrations de thyreotropine
(T. S. H.) de T4, de T3 et de r T3 au sang du cordon et
dans le liquide amniotique.
Les concentrations de T. S. H. au sang du cordon sont
elevees pendant les 4 heures suivant Tinjection de
T. R. H. et les valeurs du pic (38,0 + ou - 4,2 micro U/
ml) sont observees de 61 a 120 minutes apres T. S. H.
en comparaison avec les valeurs des temoins qui sont de
5,0 + ou - 0,3 micro U/ml.
Uelevation de la concentration fetale de T. S. H. stimule
la thyroi'de fcetale, ce qui entrame une augmentation
progressive des concentrations au sang du cordon de
T4 et de T3, mais pas de rT3. Cette elevation des
concentrations de T. S. H. au sang du cordon induite
par la T. R. H. ne s'est pas accompagnee d'une augmen-
tation des concentrations de T. S. H. dans le liquide
amniotique, celles-ci restant presque toujours inferieures
ä 0,6 micro U/ml, ce qui est la limite de sensibilite du
dosage.
Les concentrations de T4 dans le liquide amniotique
non concentre etaient ä peine detectables et n'a pas
observe de variation entre les meres traitees par T. R. H.
et celles traitees par du serum sale; la T3 amniotique
n'etait pas detectable dans les deux groupes et les
concentrations de r T3 dans le liquide amniotique etaient
comprises entre 46,4 et 55,6 ng/dl et n'etaient pas diffe-
rentes dans les deux groupes.
Ces resultats suggerent que les valeurs de la T. S. H.
dans le liquide amniotique a terme ne refletent pas une
elevation transitoire mais marquee des concentrations
de T. S. H. serique foetale et que la mesure de la T. S. H.
dans le liquide amniotique n'est probablement pas utile
pour detecter une hypothyroidie fetale primaire. II est
possible mais peu probable que les elevations a long
terme, meme les plus importantes, des concentrations
de la T. S. H. serique foetale pourraient entrainer une
augmentation des concentrations de la T. S. H. dans le
liquide amniotique. Ainsi, il apparait qu'il est de peu
d'utilito de mesurer les concentrations de T. S. H. dans le
liquide amniotique pour le diagnostic de l'hypothyro'idie
foetale.
Mots-cles: Liquide amniotique, thyreotropine, thyreotropine releasing hormone.
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